3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for X4 Pharmaceuticals Inc

X4 Pharmaceuticals (XFOR) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for X4 Pharmaceuticals Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

10 Nov, 2026

Strategic focus and financial discipline

  • Since the new management team arrived in August 2025, raised $240M and restructured leadership; operations are now almost entirely focused on the pivotal 4WARD trial.

  • Financial discipline is intended to preserve enough cash to support commercialization of mavorixafor in chronic neutropenia; cash was $188M and was expected to fund commercialization.

4WARD trial design and timing

  • Phase III, double-blind, placebo-controlled study in symptomatic primary chronic neutropenia; 126 patients randomized 1:1, with mavorixafor or placebo, each with or without G-CSF.

  • Co-primary endpoints over 12 months: reduction in annualized infection rate and ANC increase of at least 500 cells/µL on at least three occasions; trial powered for a one-third infection-rate reduction.

  • Enrollment remained on track for completion by year-end 2026; top-line 4WARD results expected by the end of Q1 2028, 8–10 weeks after the last patient enters.

  • Management characterized a one-third infection reduction as clinically meaningful, citing 6,300 primary chronic neutropenia patients hospitalized with infections in 2025 and an average four-day stay.

Treatment landscape and 4STEPS

  • Current care includes G-CSF, long-term antibiotics, or watchful waiting; G-CSF is approved for severe neutropenia, has variable use and dosing, and can involve injections, bone pain, and long-term malignancy concerns.

  • Mavorixafor could offer the first oral therapy for this disease; management sees potential use alongside G-CSF or antibiotics, with dose reductions or discontinuation possible.

  • 4STEPS is a directional study in patients already taking G-CSF, designed to inform dose titration and day-to-day prescribing; first patient expected in Q1 2027, with data anticipated alongside 4WARD results.

  • 4STEPS safety data will enter the FDA safety database; any role in label support would be considered after 4WARD results.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from X4 Pharmaceuticals